Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies

Blood Cells Mol Dis. Jul-Aug 2004;33(1):83-9. doi: 10.1016/j.bcmd.2004.03.003.

Abstract

The graft-versus-leukemia (GVL)-effect achieved by donor-derived T cells arising from transplanted allogeneic hematopoietic stem cells or given as donor-leukocyte infusions (DLI) after allogeneic transplant, demonstrates that donor-derived T cells can eradicate B-lineage malignancies. However, graft-versus-host-disease (GVHD) occurring after allogeneic hematopoietic stem-cell transplant (HSCT) or polyclonal DLI can limit the efficacy of these interventions. This toxicity can be avoided by using autologous T cells and/or tumor-specific cytotoxic T lymphocytes (CTLs). To generate antigen-specific T cells that can be derived from the allogeneic donor or the patient, we have genetically manipulated T cells to express a CD19-specific chimeric immunoreceptor. This renders T cells specific for CD19, a cell surface molecule found on B-lineage leukemia and lymphoma. This review will demonstrate the redirected specificity of CD19-specific T cells and implementation of clinical trials using these cellular agents.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antigens, CD19 / immunology
  • Graft vs Leukemia Effect
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Leukemia, B-Cell / therapy*
  • Lymphoma, B-Cell / therapy*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / transplantation

Substances

  • Antigens, CD19